Patent Law Weblog
recent posts
- Reasons for the PTAB’s Priority Determination in Broad’s Favor (Perhaps)
- Mexico Publishes Amendments to Intellectual Property Law
- PTAB (Again) Awards Priority of Invention to Broad in Interference No. 106,115
- Argentina Repeals Pharmaceutical Patent Examination Guidelines
- USPTO Moves to Protect Design Rights for Digital Innovations
about
Month: August 2007
-
August 23-24, 2007 – Current Issues in Complex IP Licensing: Business and Legal Factors for Licensing Transactions (Law Seminars International) – Seattle, WA August 24, 2007 – Managing Patent Prosecution and Litigation: New Regulations, Rules and Challenges, along with Practical Tips for Success (Law Seminars International) – San Francisco, CA September 6-7, 2007 – Emerging…
-
The American Law Institute (ALI) and American Bar Association (ABA) will be holding a conference entitled: "Emerging Issues in Biotechnology Law" on September 6-7, 2007 in Washington, D.C. The conference will address current issues in biotechnology and related legal developments, including collaborations with academia, business alliances, working with the federal government and Department of Defense,…
-
By Donald Zuhn — On Tuesday Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,252,817. The ‘817 patent, which relates to methods for treating cell proliferative disorders such as neoplasms by administering modified modified herpes simplex viruses (HSV) to proliferating cells having an activated Ras-pathway, was the twenty-second U.S.…
-
By Jason Derry — Archemix Corp. has announced alliances with Isis Pharmaceuticals and SomaLogic. Archemix, a biotechnology company located in Cambridge, MA, filed an initial public offering July 25, 2007. Archemix focuses on developing apatmers as directed therapeutics to prevent and treat chronic and acute diseases. One of Archemix’s lead drug candidates is…
-
By Donald Zuhn — Rosetta Genomics, Ltd. announced on July 31, 2007 that it had been granted U.S. Patent No. 7,250,496. While the ‘496 patent discloses two large groups of genes: 20,600 genomic address messenger (GAM) genes, which selectively inhibit the translation of disease-associated target genes, and 6,635 genomic record (GR) genes –…
-
By Donald Zuhn — As we reported yesterday, the San Francisco Chronicle waded into the patent reform debate over the weekend, appearing to have aligned itself with the "laptop" (or tech) group over the "pill bottle" (or biotech/pharma) group. In making a case for the tech firms’ position that patent reform is "badly…
-
By Kevin E. Noonan — Horsham, Pennsylvania biotech company Nucleonics, Inc. announced today that it has filed a petition with the Court of Appeals for the Federal Circuit for rehearing en banc of the Court’s July 20, 2007 decision upholding dismissal of its declaratory judgment counterclaims against Benetic Australia Ltd. over patents on…
-
By Donald Zuhn — In an editorial appearing in Sunday’s edition of the San Francisco Chronicle, the Bay area newspaper appears to have, perhaps not surprisingly, taken sides with tech companies on the issue of patent reform. In an editorial entitled "The laptop vs. the pill bottle," the Chronicle acknowledges the ongoing battle…
-
By Kwame Mensah — Digilab Peptidomics announced last month that the U.S. Patent and Trademark Office had granted U.S. Patent No. 7,202,044, which is directed to a panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. According to the company’s press release, by using proprietary Peptidomics® technologies,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Lonza Group AG v. Northwest Biotherapeutics Inc.1:07-cv-00467; filed July 27, 2007 in the District Court of Delaware Infringement of U.S. Patent Nos.…
Patent Docs 